Aptose Biosciences Inc.

Aptose Biosciences Inc.verified

APTO

Price:

$0.2488

Market Cap:

$14.81M

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic...[Read more]

Industry

Biotechnology

IPO Date

1992-03-16

Stock Exchange

NASDAQ

Ticker

APTO

The Enterprise Value as of December 2024 (TTM) for Aptose Biosciences Inc. (APTO) is 25.53M

According to Aptose Biosciences Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 25.53M. This represents a change of 104.69% compared to the average of 12.47M of the last 4 quarters.

Aptose Biosciences Inc. (APTO) Historical Enterprise Value (quarterly & annually)

How has APTO Enterprise Value performed in the past?

The mean historical Enterprise Value of Aptose Biosciences Inc. over the last ten years is -24379061.38. The current 25.53M Enterprise Value has changed -10572.05% with respect to the historical average. Over the past ten years (40 quarters), APTO's Enterprise Value was at its highest in in the June 2023 quarter at 21.73M. The Enterprise Value was at its lowest in in the December 2020 quarter at -90358740.00.

Quarterly (TTM)
Annual

Average

-24379061.38

Median

-9158796.97

Minimum

-92422600.38

Maximum

8.92M

Aptose Biosciences Inc. (APTO) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Aptose Biosciences Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 437.24%

Maximum Annual Enterprise Value = 8.92M

Minimum Annual Increase = -127.79%

Minimum Annual Enterprise Value = -92422600.38

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20238.92M-127.79%
2022-32099342.865.17%
2021-30522260.90-66.98%
2020-92422600.3855.73%
2019-59349525.67437.24%
2018-11047213.9451.95%
2017-7270380.007.67%
2016-6752335.007.47%
2015-6283025.00-9.79%
2014-6964630.00-47.19%

Aptose Biosciences Inc. (APTO) Average Enterprise Value

How has APTO Enterprise Value performed in the past?

The current Enterprise Value of Aptose Biosciences Inc. (APTO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-17900301.25

5-year avg

-41094605.96

10-year avg

-24379061.38

Aptose Biosciences Inc. (APTO) Enterprise Value vs. Peers

How is APTO’s Enterprise Value compared to its peers?

Aptose Biosciences Inc.’s Enterprise Value is less than CytomX Therapeutics, Inc. (55.32M), less than Instil Bio, Inc. (220.42M), greater than Neoleukin Therapeutics, Inc. (-6333315.00), greater than Spero Therapeutics, Inc. (-21358605.00), less than Assembly Biosciences, Inc. (67.83M), less than Fortress Biotech, Inc. (60.71M), greater than Mustang Bio, Inc. (5.46M), greater than Achilles Therapeutics plc (-42104641.00), less than Fortress Biotech, Inc. (60.71M), less than Gain Therapeutics, Inc. (30.36M), greater than TFF Pharmaceuticals, Inc. (-2265301.00), less than aTyr Pharma, Inc. (138.44M), greater than IN8bio, Inc. (18.87M), greater than Lantern Pharma Inc. (24.76M), greater than Affimed N.V. (22.92M), less than Leap Therapeutics, Inc. (48.29M), less than Adaptimmune Therapeutics plc (58.35M), less than Corvus Pharmaceuticals, Inc. (288.04M), less than Longboard Pharmaceuticals, Inc. (2.32B), greater than TRACON Pharmaceuticals, Inc. (-6160275.00), greater than Oncternal Therapeutics, Inc. (-11329454.00), less than Aeglea BioTherapeutics, Inc. (1.31B),

Build a custom stock screener for Aptose Biosciences Inc. (APTO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aptose Biosciences Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aptose Biosciences Inc. (APTO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aptose Biosciences Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Aptose Biosciences Inc.'s Enterprise Value?

What is the highest Enterprise Value for Aptose Biosciences Inc. (APTO)?

What is the 3-year average Enterprise Value for Aptose Biosciences Inc. (APTO)?

What is the 5-year average Enterprise Value for Aptose Biosciences Inc. (APTO)?

How does the current Enterprise Value for Aptose Biosciences Inc. (APTO) compare to its historical average?